Heparin is procoagulant in the absence of antithrombin

Thrombosis and Haemostasis

Volumn 100, Issue 1, 2008, Pages 160-162

  Smith, Stephanie A ^a   Morrissey, James H ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; AV 513; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; ENOXAPARIN; HEPARIN; POLYPHOSPHATE; PROCOAGULANT; PROTEOHEPARAN SULFATE; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANGIOGENESIS; APOPTOSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; CELL ADHESION; DRUG MECHANISM; INFLAMMATION; LETTER; PRIORITY JOURNAL; THROMBOCYTE FUNCTION;

ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; COAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR VA; FACTOR XA; HEPARIN COFACTOR II; HUMANS; LIPOPROTEINS; POLYPHOSPHATES; THROMBIN;

EID: 46749120559     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-05-0275     Document Type: Letter

References (13)

1. th ed. Lippincott Williams and Wilkins, 2006: 271-283.
2. Fonseca RJ, Mourao PA. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Thromb Haemost 2006; 96: 822-829.
3. Melo FR, Mourao PA. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Thromb Haemost 2008; 99: 531-538.
4. Lindahl U. Heparan sulfate-protein interactions - a concept for drug design? Thromb Haemost 2007; 98: 109-115.
5. Marcum JA, Atha DH, Fritze LM, et al. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986; 261: 7507-7517.
6. Kojima T, Leone CW, Marchildon GA, et al. Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem 1992; 267: 4859-4869.
7. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; in press.
8. Liu T, Scallan CD, Broze GJ, Jr., et al. Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP). Thromb Haemost 2006; 95: 68-76.
9. Mutch NJ, Johnson KW, Morrissey JH. Non-anticoagulant sulfated polysaccharides enhance thrombin generation by accelerating factor V activation. J Thromb Haemost 2007; 5 (Suppl 2): O-M-094.
10. Kornberg A, Rao NN, Ault-Riche D. Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem 1999; 68: 89-125.
11. Smith SA, Mutch NJ, Baskar D, et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
12. Mast AE, Broze GJ, Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 1996; 87: 1845-1850.
13. Fareed J, Hoppensteadt D, Schultz C, et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Curr Pharm Des 2004; 10: 983-999.